Shots:
- Incyte has partnered with Genesis to advance research, discovery, & development of novel small molecules using GEMS (Genesis Exploration of Molecular Space) AI platform, initially focusing on targets selected by Incyte
- As per the agreement, Incyte will gain exclusive rights to develop & commercialize products arising from this deal in exchange for $30M upfront, ~$295M/target in development, regulatory & commercial milestones, plus sales-based tiered royalties
- In addition, Genesis & Incyte have agreed to collaborate on 2 initial targets, with Incyte retaining the option to nominate an additional target for a predetermined fee
Ref: Incyte | Image: Incyte & Genesis
Related News:- Incyte Highlights the P-III (inMIND) Study Data of Monjuvi (Tafasitamab) to Treat R/R Follicular Lymphoma at ASH 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
